Merck & Co., Inc. — Director's Dealing 2019

Apr 4, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: NGM BIOPHARMACEUTICALS INC (NGM)
CIK: 0001426332
Period of Report: 2019-04-03

Reporting Person: Merck & Co., Inc. (10% Owner)
Reporting Person: Merck Sharp & Dohme Corp. (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series E Convertible Preferred Stock	$		Common Stock (8833333)		Indirect

Footnotes

F1: The number of shares of common stock reflects a 1-for-2 reverse stock split, which became effective March 22, 2019. Each share of the Issuer's Series E Preferred Stock is convertible into the Issuer's common stock on a 1-for-2 basis and has no expiration date. The number of underlying shares of common stock reported in Column 3 reflects the 1-for-2 reverse stock split pursuant to which every 2 shares of Preferred Stock will convert into one share of common stock of the Issuer, effective upon the closing of the Issuer's initial public offering, for no additional consideration.

F2: These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. ("Merck"). Merck is an indirect beneficial owner of the reported securities.